The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  De Wolf, Katrien ^a   Vermaelen, Karim ^a   De Meerleer, Gert ^a   Lambrecht, Bart N ^b,c,d   Ost, Piet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

antitumor immunity; immunotherapy; radiotherapy; renal cell carcinoma; targeted therapy; treatment combination

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGINASE 1; AXITINIB; BEVACIZUMAB; CALRETICULIN; CXCL9 CHEMOKINE; EVEROLIMUS; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; PAZOPANIB; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SORAFENIB; STAT3 PROTEIN; SUNITINIB; T LYMPHOCYTE RECEPTOR; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RADIATION DOSE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84940707462     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1042198     Document Type: Article

References (118)

1. F.Audenet, D.R.Yates, G.Cancel-Tassin, O.Cussenot, M.Roupret. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 2012; 109(12):1864-70; PMID:22035299; http://dx.doi.org/10.1111/j.1464-410X.2011.10661.x
2. D.A.Swanson. Surgery for metastases of renal cell carcinoma. Scand J Surg 2004; 93(2):150-5; PMID:15285568
3. B.Ljungberg, N.C.Cowan, D.C.Hanbury, M.Hora, M.A.Kuczyk, A.S.Merseburger, J.J.Patard, P.F.Mulders, I.C.Sinescu. European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58(3):398-406; PMID:20633979; http://dx.doi.org/10.1016/j.eururo.2010.06.032
4. C.Coppin, L.Le, F.Porzsolt, T.Wilt. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008(2):CD006017; PMID:18425931; http://dx.doi.org/10.1002/14651858.CD006017.pub2
5. R.Iacovelli, D.Alesini, A.Palazzo, P.Trenta, M.Santoni, L.De Marchis, S.Cascinu, G.Naso, E.Cortesi. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev 2014; 40(2):271-5; PMID:24070900; http://dx.doi.org/10.1016/j.ctrv.2013.09.003
6. J.A.Klapper, S.G.Downey, F.O.Smith, J.C.Yang, M.S.Hughes, U.S.Kammula, R.M.Sherry, R.E.Royal, S.M.Steinberg, S.Rosenberg. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113(2):293-301; PMID:18457330; http://dx.doi.org/10.1002/cncr.23552
7. M.M.Elhilali, M.Gleave, Y.Fradet, I.Davis, P.Venner, F.Saad, L.Klotz, R.Moore, S.Ernst, V.Paton. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int 2000; 86(6):613-8; PMID:11069364; http://dx.doi.org/10.1046/j.1464-410x.2000.00880.x
8. R.A.Rendon. New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer. Can Urol Assoc J 2007; 1(2 Suppl):S62-8; PMID:18542787; http://dx.doi.org/10.5489/cuaj.69
9. H.Ishiyama, B.S.Teh, H.Ren, S.Chiang, A.Tann, A.I.Blanco, A.C.Paulino, R.Amato. Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin Genitourin Cancer 2012; 10(3):196-8; PMID:22409865; http://dx.doi.org/10.1016/j.clgc.2012.01.004
10. P.J.Wersall, H.Blomgren, P.Pisa, I.Lax, K.M.Kalkner, C.Svedman. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 2006; 45(4):493-7; PMID:16760190; http://dx.doi.org/10.1080/02841860600604611
11. E.F.Stamell, J.D.Wolchok, S.Gnjatic, N.Y.Lee, I.Brownell. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013; 85(2):293-5; PMID:22560555; http://dx.doi.org/10.1016/j.ijrobp.2012.03.017
12. M.A.Postow, M.K.Callahan, C.A.Barker, Y.Yamada, J.Yuan, S.Kitano, Z.Mu, T.Rasalan, M.Adamow, E.Ritter. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366(10):925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
13. S.K.Seung, B.D.Curti, M.Crittenden, E.Walker, T.Coffey, J.C.Siebert, W.Miller, R.Payne, L.Glenn, A.Bageac et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci Transl Med 2012; 4(137):137ra74; PMID:22674552; http://dx.doi.org/10.1126/scitranslmed.3003649
14. M.Durante, N.Reppingen, K.D.Held. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med 2013; 19(9):565-82; PMID:23831337; http://dx.doi.org/10.1016/j.molmed.2013.05.007
15. R.M.Snow, P.F.Schellhammer. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982; 20(2):177-81; PMID:7112827; http://dx.doi.org/10.1016/0090-4295(82)90356-9
16. R.F.Meredith, K.P.Raisch, J.A.Bonner, D.J.Buchsbaum, W.E.Grizzle, Y.Li, S.A.Spencer. Pazopanib combined with radiation: in vivo model of interaction. Cancer Biother Radiopharm 2014; 29(6):247-50; PMID:24945464; http://dx.doi.org/10.1089/cbr.2013.1583
17. J.Kao, C.T.Chen, C.C.Tong, S.H.Packer, M.Schwartz, S.H.Chen, M.W.Sung. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol 2014; 9(2):145-53; PMID:23660867; http://dx.doi.org/10.1007/s11523-013-0280-y
18. G.Venton, A.Ducournau, E.Gross, E.Lechevallier, A.Rochwerger, G.Curvale, J.V.Zink, S.Salas, J.L.Deville. Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma. Anticancer Res 2012; 32(2):701-5; PMID:22287766
19. J.Zeng, A.P.See, J.Phallen, C.M.Jackson, Z.Belcaid, J.Ruzevick, N.Durham, C.Meyer, T.J.Harris, E.Albesiano et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013; 86(2):343-9; PMID:23462419; http://dx.doi.org/10.1016/j.ijrobp.2012.12.025
20. L.Deng, H.Liang, B.Burnette, M.Beckett, T.Darga, R.R.Weichselbaum, Y.X.Fu. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124(2):687-95; PMID:24382348; http://dx.doi.org/10.1172/JCI67313
21. G.Dranoff. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4(1):11-22; PMID:14708024; http://dx.doi.org/10.1038/nrc1252
22. G.A.Rabinovich, D.Gabrilovich, E.M.Sotomayor. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol 2007; 25:267-96; PMID:17134371; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141609
23. L.Teng, Y.Chen, D.Ding, H.Dai, G.Liu, C.Li. Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells. Int Urol Nephrol 2013; 46(5):915-20; PMID:24202958; http://dx.doi.org/10.1007/s11255-013-0595-8
24. B.Frankenberger, E.Noessner, D.J.Schendel. Immune suppression in renal cell carcinoma. Semin Cancer Biol 2007; 17(4):330-43; PMID:17656104; http://dx.doi.org/10.1016/j.semcancer.2007.06.004
25. E.Jonasch, P.A.Futreal, I.J.Davis, S.T.Bailey, W.Y.Kim, J.Brugarolas, A.J.Giaccia, G.Kurban, A.Pause, J.Frydman et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012; 10(7):859-80; PMID:22638109; http://dx.doi.org/10.1158/1541-7786.MCR-12-0117
26. P.Raber, A.C.Ochoa, P.C.Rodriguez. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012; 41(6-7):614-34; PMID:23017138; http://dx.doi.org/10.3109/08820139.2012.680634
27. D.Lindau, P.Gielen, M.Kroesen, P.Wesseling, G.J.Adema. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138(2):105-15; PMID:23216602; http://dx.doi.org/10.1111/imm.12036
28. A.C.Ochoa, A.H.Zea, C.Hernandez, P.C.Rodriguez. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13(2 Pt 2):721s-6s; PMID:17255300; http://dx.doi.org/10.1158/1078-0432.CCR-06-2197
29. B.Seliger. Immune Escape Mechanisms of Renal Cell Carcinoma. Eur Urol Suppl 2007; 6(10):616-22; PMID: 18292536; http://dx.doi.org/10.1016/j.eursup.2007.03.009
30. M.Z.Noman, S.Buart, J.Van Pelt, C.Richon, M.Hasmim, N.Leleu, W.M.Suchorska, A.Jalil, Y.Lecluse, F.El Hage et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182(6):3510-21; PMID:19265129; http://dx.doi.org/10.4049/jimmunol.0800854
31. C.Rebe, F.Vegran, H.Berger, F.Ghiringhelli. STAT3 activation: A key factor in tumor immunoescape. JAKSTAT 2013; 2(1):e23010; PMID:24058791; http://dx.doi.org/10.4161/jkst.23010
32. L.Avalle, S.Pensa, G.Regis, F.Novelli, V.Poli. STAT1 and STAT3 in tumorigenesis: A matter of balance. JAKSTAT 2012; 1(2):65-72; PMID:24058752; http://dx.doi.org/10.4161/jkst.20045
33. Q.Xu, J.Briggs, S.Park, G.Niu, M.Kortylewski, S.Zhang, T.Gritsko, J.Turkson, H.Kay, G.L.Semenza et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24(36):5552-60; PMID:16007214; http://dx.doi.org/10.1038/sj.onc.1208719
34. M.M.Baldewijns, I.J.van Vlodrop, P.B.Vermeulen, P.M.Soetekouw, M.van Engeland, A.P.de Bruine. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010; 221(2):125-38; PMID:20225241; http://dx.doi.org/10.1002/path.2689
35. C.C.Yang, K.C.Chu, W.M.Yeh. Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J Clin Lab Anal 2003; 17(3):85-9; PMID:12696078; http://dx.doi.org/10.1002/jcla.10074
36. J.Jacobsen, K.Grankvist, T.Rasmuson, B.Ljungberg. Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 2002; 11(3):245-52; PMID:12131658
37. A.Schietinger, P.D.Greenberg. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2014; 35(2):51-60; PMID:24210163; http://dx.doi.org/10.1016/j.it.2013.10.001
38. B.Seliger, D.Quandt. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012; 61(8):1327-41; PMID:22695874; http://dx.doi.org/10.1007/s00262-012-1293-6
39. R.H.Thompson, H.Dong, C.M.Lohse, B.C.Leibovich, M.L.Blute, J.C.Cheville, E.D.Kwon. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clinical Cancer Res 2007; 13(6):1757-61; PMID:17363529; http://dx.doi.org/10.1158/1078-0432.CCR-06-2599
40. M.J.Kang, K.M.Kim, J.S.Bae, H.S.Park, H.Lee, M.J.Chung, W.S.Moon, D.G.Lee, K.Y.Jang. Tumor-infiltrating PD1-Positive lymphocytes and FoxP3-positive regulatory t cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol 2013; 6(3):282-9; PMID:23730407; http://dx.doi.org/10.1593/tlo.13256
41. A.E.Krambeck, R.H.Thompson, H.Dong, C.M.Lohse, E.S.Park, S.M.Kuntz, B.C.Leibovich, M.L.Blute, J.C.Cheville, E.D.Kwon. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006; 103(27):10391-6; PMID:16798883; http://dx.doi.org/10.1073/pnas.0600937103
42. J.Yuan, B.Jiang, H.Zhao, Q.Huang. Prognostic implication of TIM-3 in clear cell renal cell carcinoma. Neoplasma 2014; 61(1):35-40; PMID:24195506; http://dx.doi.org/10.4149/neo_2014_006
43. J.Gao, C.Bernatchez, P.Sharma, L.G.Radvanyi, P.Hwu. Advances in the development of cancer immunotherapies. Trends Immunol 2013; 34(2):90-8; PMID:23031830; http://dx.doi.org/10.1016/j.it.2012.08.004
44. P.A.Savage, S.Malchow, D.S.Leventhal. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 2013; 34(1):33-40; PMID:22999714; http://dx.doi.org/10.1016/j.it.2012.08.005
45. T.L.Whiteside. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16(1):3-15; PMID:16153857; http://dx.doi.org/10.1016/j.semcancer.2005.07.008
46. D.H.Munn, A.L.Mellor. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013; 34(3):137-43; PMID:23103127; http://dx.doi.org/10.1016/j.it.2012.10.001
47. S.R.Dannenmann, J.Thielicke, M.Stockli, C.Matter, L.von Boehmer, V.Cecconi, T.Hermanns, L.Hefermehl, P.Schraml, H.Moch et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013; 2(3):e23562; PMID:23687622; http://dx.doi.org/10.4161/onci.23562
48. F.Liotta, M.Gacci, F.Frosali, V.Querci, G.Vittori, A.Lapini, V.Santarlasci, S.Serni, L.Cosmi, L.Maggi et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2011; 107(9):1500-6; PMID:20735382; http://dx.doi.org/10.1111/j.1464-410X.2010.09555.x
49. E.Noessner, D.Brech, A.N.Mendler, I.Masouris, R.Schlenker, P.U.Prinz. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1(8):1451-3; PMID:23243626; http://dx.doi.org/10.4161/onci.21356
50. J.M.Cozar, J.Canton, M.Tallada, A.Concha, T.Cabrera, F.Garrido, F.Ruiz-Cabello Osuna. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 2005; 54(9):858-66; PMID:15887015; http://dx.doi.org/10.1007/s00262-004-0646-1
51. G.Chitadze, J.Bhat, M.Lettau, O.Janssen, D.Kabelitz. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013; 78(2):120-9; PMID:23679194; http://dx.doi.org/10.1111/sji.12072
52. I.Daurkin, E.Eruslanov, T.Stoffs, G.Q.Perrin, C.Algood, S.M.Gilbert, C.J.Rosser, L.M.Su, J.Vieweg, S.Kusmartsev. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res 2011; 71(20):6400-9; PMID:21900394; http://dx.doi.org/10.1158/0008-5472.CAN-11-1261
53. M.Santoni, F.Massari, C.Amantini, M.Nabissi, F.Maines, L.Burattini, R.Berardi, G.Santoni, R.Montironi, G.Tortora et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2013; 62(12):1757-68; PMID:24132754; http://dx.doi.org/10.1007/s00262-013-1487-6
54. R.Kolesnick, Z.Fuks. Radiation and ceramide-induced apoptosis. Oncogene 2003; 22(37):5897-906; PMID:12947396; http://dx.doi.org/10.1038/sj.onc.1206702
55. G.De Meerleer, V.Khoo, B.Escudier, S.Joniau, A.Bossi, P.Ost, A.Briganti, V.Fonteyne, M.Van Vulpen, N.Lumen et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 2014; 15(4):e170-7; PMID:24694640; http://dx.doi.org/10.1016/S1470-2045(13)70569-2
56. G.Kothari, F.Foroudi, S.Gill, N.M.Corcoran, S.Siva. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 2015; 54(2):148-57; PMID:25140860; http://dx.doi.org/10.3109/0284186X.2014.939298
57. R.Manon, A.O'Neill, J.Knisely, M.Werner-Wasik, H.M.Lazarus, H.Wagner, M.Gilbert, M.Mehta; Eastern Cooperative Oncology Group. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 2005; 23(34):8870-6; PMID:16314647; http://dx.doi.org/10.1200/JCO.2005.01.8747
58. C.Svedman, P.Sandstrom, P.Pisa, H.Blomgren, I.Lax, K.M.Kalkner, S.Nilsson, P.Wersäll. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006; 45(7):870-5; PMID:16982552; http://dx.doi.org/10.1080/02841860600954875
59. A.Gupta, H.C.Probst, V.Vuong, A.Landshammer, S.Muth, H.Yagita, R.Schwendener, M.Pruschy, A.Knuth, M.van den Broek. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 2012; 189(2):558-66; PMID:22685313; http://dx.doi.org/10.4049/jimmunol.1200563
60. S.R.Gameiro, M.L.Jammeh, M.M.Wattenberg, K.Y.Tsang, S.Ferrone, J.W.Hodge. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014; 5(2):403-16; PMID:24480782
61. C.T.Garnett, C.Palena, M.Chakraborty, K.Y.Tsang, J.Schlom, J.W.Hodge. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64(21):7985-94; PMID:15520206; http://dx.doi.org/10.1158/0008-5472.CAN-04-1525
62. S.Demaria, S.C.Formenti. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012; 2:153; PMID:23112958; http://dx.doi.org/10.3389/fonc.2012.00153
63. J.W.Hodge, C.Guha, J.Neefjes, J.L.Gulley. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology 2008; 22(9):1064-70; discussion 75, 80-1, 84; PMID: 18777956
64. L.Kulzer, Y.Rubner, L.Deloch, A.Allgauer, B.Frey, R.Fietkau, J.Dörrie, N.Schaft, U.S.Gaipl. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol 2014; 11(4):328-36; PMID:24512329; http://dx.doi.org/10.3109/1547691X.2014.880533
65. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
66. A.M.Dudek, A.D.Garg, D.V.Krysko, D.De Ruysscher, P.Agostinis. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; 24(4):319-33; PMID:23391812; http://dx.doi.org/10.1016/j.cytogfr.2013.01.005
67. S.L.Shiao, L.M.Coussens. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010; 15(4):411-21; PMID:21161342; http://dx.doi.org/10.1007/s10911-010-9194-9
68. M.B.Fuertes, S.R.Woo, B.Burnett, Y.X.Fu, T.F.Gajewski. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013; 34(2):67-73; PMID:23122052; http://dx.doi.org/10.1016/j.it.2012.10.004
69. C.Twyman-Saint Victor, A.J.Rech, A.Maity, R.Rengan, K.E.Pauken, E.Stelekati, J.L.Benci, B.Xu, H.Dada, P.M.Odorizzi et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520(7547):373-7; PMID:25754329; http://dx.doi.org/10.1038/nature14292
70. A.A.Lugade, E.W.Sorensen, S.A.Gerber, J.P.Moran, J.G.Frelinger, E.M.Lord. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008; 180(5):3132-9; PMID: 18292536; http://dx.doi.org/10.4049/jimmunol.180.5.3132
71. S.A.Gerber, A.L.Sedlacek, K.R.Cron, S.P.Murphy, J.G.Frelinger, E.M.Lord. IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol 2013; 182(6):2345-54; PMID:23583648; http://dx.doi.org/10.1016/j.ajpath.2013.02.041
72. S.E.Finkelstein, R.Timmerman, W.H.McBride, D.Schaue, S.E.Hoffe, C.A.Mantz, G.D.Wilson. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Devel Immunol 2011; 2011:439752; PMID:22162711; http://dx.doi.org/10.1155/2011/439752
73. M.J.Gough, K.Young, M.Crittenden. The impact of the myeloid response to radiation therapy. Clin Dev Immunol 2013; 2013:281958; PMID:23653658; http://dx.doi.org/10.1155/2013/281958
74. M.Chiriva-Internati, F.Grizzi, J.Pinkston, K.J.Morrow, N.D'Cunha, E.E.Frezza, P.C.Muzzio, W.M.Kast, E.Cobos. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 2006; 42(3-4):89-95; PMID:16759154; http://dx.doi.org/10.1290/0508054.1
75. H.Liang, L.Deng, B.Burnette, R.R.Weichselbaum, Y.X.Fu. Radiation-induced tumor dormancy reflects an equilibrium between the proliferation and T lymphocyte-mediated death of malignant cells. Oncoimmunology 2013; 2(9):e25668; PMID:24319637; http://dx.doi.org/10.4161/onci.25668
76. J.Y.Lim, S.A.Gerber, S.P.Murphy, E.M.Lord. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 2014; 63(3):259-71; PMID:24357146; http://dx.doi.org/10.1007/s00262-013-1506-7
77. H.Ueno, E.Klechevsky, R.Morita, C.Aspord, T.Cao, T.Matsui, T.Di Pucchio, J.Connolly, J.W.Fay, V.Pascual, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118-42; PMID:17850486; http://dx.doi.org/10.1111/j.1600-065X.2007.00551.x
78. M.B.Bernstein, C.T.Garnett, H.Zhang, A.Velcich, M.M.Wattenberg, S.R.Gameiro, S.Kalnicki, J.W.Hodge, C.Guha. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 2014; 29(4):153-61; PMID:24693958; http://dx.doi.org/10.1089/cbr.2013.1578
79. Y.Ma, O.Kepp, F.Ghiringhelli, L.Apetoh, L.Aymeric, C.Locher, A.Tesniere, I.Martins, A.Ly, N.M.Haynes et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010; 22(3):113-24; PMID:20403709; http://dx.doi.org/10.1016/j.smim.2010.03.001
80. S.Demaria, S.C.Formenti. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012; 2:95; PMID:22937524; http://dx.doi.org/10.3389/fonc.2012.00095
81. Y.C.Zhou, J.Y.Liu, J.Li, J.Zhang, Y.Q.Xu, H.W.Zhang, L.B.Qiu, G.R.Ding, X.M.Su, Mei-Shi et al. Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition. Int J Radiat Oncol Biol Phys 2011; 81(5):1530-7; PMID:22115555; http://dx.doi.org/10.1016/j.ijrobp.2011.06.1956
82. W.J.Kil, P.J.Tofilon, K.Camphausen. Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol 2012; 7:25; PMID:22356893; http://dx.doi.org/10.1186/1748-717X-7-25
83. S.C.Formenti, S.Demaria. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105(4):256-65; PMID:23291374; http://dx.doi.org/10.1093/jnci/djs629
84. D.Schaue, J.A.Ratikan, K.S.Iwamoto, W.H.McBride. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012; 83(4):1306-10; PMID:22208977; http://dx.doi.org/10.1016/j.ijrobp.2011.09.049
85. J.Y.Kim, Y.O.Son, S.W.Park, J.H.Bae, J.S.Chung, H.H.Kim, B.S.Chung, S.H.Kim, C.D.Kang. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006; 38(5):474-84; PMID:17079863; http://dx.doi.org/10.1038/emm.2006.56
86. N.Nausch, A.Cerwenka. NKG2D ligands in tumor immunity. Oncogene 2008; 27(45):5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
87. H.G.Ljunggren, K.Karre. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 1990; 11(7):237-44; PMID:2201309; http://dx.doi.org/10.1016/0167-5699(90)90097-S
88. O.Z.Lerman, M.R.Greives, S.P.Singh, V.D.Thanik, C.C.Chang, N.Seiser, D.J.Brown, D.Knobel, R.J.Schneider, S.C.Formenti et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction. Blood 2010; 116(18):3669-76; PMID:20631377; http://dx.doi.org/10.1182/blood-2009-03-213629
89. R.Duerst, K.Werberig. Cells of the J774 macrophage cell line are primed for antibody-dependent cell-mediated cytotoxicity following exposure to gamma-irradiation. Cell Immunol 1991; 136(2):361-72; PMID:1831405; http://dx.doi.org/10.1016/0008-8749(91)90359-J
90. L.E.Lambert, D.M.Paulnock. Modulation of macrophage function by gamma-irradiation. Acquisition of the primed cell intermediate stage of the macrophage tumoricidal activation pathway. J Immunol 1987; 139(8):2834-41; PMID:3116096
91. L.C.McKinney, E.M.Aquilla, D.Coffin, D.A.Wink, Y.Vodovotz. Ionizing radiation potentiates the induction of nitric oxide synthase by interferon-gamma and/or lipopolysaccharide in murine macrophage cell lines. Role of tumor necrosis factor-alpha. Ann N Y Acad Sci 2000; 899:61-8; PMID:9766626; http://dx.doi.org/10.1111/j.1749-6632.2000.tb06176.x
92. D.Schaue, E.D.Micewicz, J.A.Ratikan, M.W.Xie, G.Cheng, W.H.McBride. Radiation and inflammation. Semin Radiat Oncol 2015; 25(1):4-10; PMID:25481260; http://dx.doi.org/10.1016/j.semradonc.2014.07.007
93. F.Klug, H.Prakash, P.E.Huber, T.Seibel, N.Bender, N.Halama, C.Pfirschke, R.H.Voss, C.Timke, L.Umansky et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24(5):589-602; PMID:24209604; http://dx.doi.org/10.1016/j.ccr.2013.09.014
94. C.Timke, H.S.Winnenthal, F.Klug, F.F.Roeder, A.Bonertz, C.Reissfelder, N.Rochet, M.Koch, C.Tjaden, M.W.Buechler et al. Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer. BMC Cancer 2011; 11:134; PMID:21489291; http://dx.doi.org/10.1186/1471-2407-11-134
95. P.J.Coates, J.K.Rundle, S.A.Lorimore, E.G.Wright. Indirect macrophage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Res 2008; 68(2):450-6; PMID:18199539; http://dx.doi.org/10.1158/0008-5472.CAN-07-3050
96. M.Vanneman, G.Dranoff. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12(4):237-51; PMID:22437869; http://dx.doi.org/10.1038/nrc3237
97. C.Porta, C.Paglino, I.Imarisio, C.Ganini, P.Pedrazzoli. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer 2011; 2:333-8; PMID:21716852; http://dx.doi.org/10.7150/jca.2.333
98. H.Xin, C.Zhang, A.Herrmann, Y.Du, R.Figlin, H.Yu. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69(6):2506-13; PMID:19244102; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323
99. M.Kujawski, C.Zhang, A.Herrmann, K.Reckamp, A.Scuto, M.Jensen, J.Deng, S.Forman, R.Figlin, H.Yu. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010; 70(23):9599-610; PMID:21118964; http://dx.doi.org/10.1158/0008-5472.CAN-10-1293
100. J.Ozao-Choy, G.Ma, J.Kao, G.X.Wang, M.Meseck, M.Sung, M.Schwartz, C.M.Divino, P.Y.Pan, S.H.Chen. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69(6):2514-22; PMID:19276342; http://dx.doi.org/10.1158/0008-5472.CAN-08-4709
101. A.El Kaffas, A.Giles, G.J.Czarnota. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound. Angiogenesis 2013; 16(2):443-54; PMID:23314761; http://dx.doi.org/10.1007/s10456-012-9329-2
102. J.P.Truman, M.Garcia-Barros, M.Kaag, D.Hambardzumyan, B.Stancevic, M.Chan, Z.Fuks, R.Kolesnick, A.Haimovitz-Friedman. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PloS One 2010; 5(9); PMID:20941382; http://dx.doi.org/10.1371/annotation/6e222ad5-b175-4a00-9d04-4d120568a897
103. M.M.Hipp, N.Hilf, S.Walter, D.Werth, K.M.Brauer, M.P.Radsak, T.Weinschenk, H.Singh-Jasuja, P.Brossart. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111(12):5610-20; PMID:18310500; http://dx.doi.org/10.1182/blood-2007-02-075945
104. D.Dangaj, E.Lanitis, A.Zhao, S.Joshi, Y.Cheng, R.Sandaltzopoulos, H.J.Ra, G.Danet-Desnoyers, D.J.PowellJr, N.Scholler. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res 2013; 73(15):4820-9; PMID:23722540; http://dx.doi.org/10.1158/0008-5472.CAN-12-3457
105. I.M.Desar, J.H.Jacobs, C.A.Hulsbergen-vandeKaa, W.J.Oyen, P.F.Mulders, W.T.van der Graaf, G.J.Adema, C.M.van Herpen, I.J.de Vries. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 2011; 129(2):507-12; PMID:20839259; http://dx.doi.org/10.1002/ijc.25674
106. K.Kohga, T.Takehara, T.Tatsumi, H.Ishida, T.Miyagi, A.Hosui, N.Hayashi. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010; 51(4):1264-73; PMID:20099300; http://dx.doi.org/10.1002/hep.23456
107. J.C.Lin, C.L.Liu, J.J.Lee, T.P.Liu, W.C.Ko, Y.C.Huang, C.H.Wu, Y.J.Chen. Sorafenib induces autophagy and suppresses activation of human macrophage. Int Immunopharmacol 2013; 15(2):333-9; PMID:23337882; http://dx.doi.org/10.1016/j.intimp.2013.01.006
108. S.Gupta, P.E.Spiess. The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol 2013; 5(5):223-32; PMID:24082917; http://dx.doi.org/10.1177/1756287213495099
109. E.R.Kessler, D.W.Bowles, T.W.Flaig, E.T.Lam, A.Jimeno. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today 2012; 48(10):633-44; PMID:23110259; http://dx.doi.org/10.1358/dot.2012.48.10.1860768
110. A.Bose, D.B.Lowe, A.Rao, W.J.Storkus. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012; 22(3):236-43; PMID:22504156; http://dx.doi.org/10.1097/CMR.0b013e3283538293
111. S.Goyal, S.Shah, A.J.Khan, H.Danish, B.G.Haffty. Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib. ISRN Oncol 2012; 2012:896202; PMID:23304555; http://dx.doi.org/10.5402/2012/896202
112. T.Weichhart, M.D.Saemann. The multiple facets of mTOR in immunity. Trends Immunol 2009; 30(5):218-26; PMID:19362054; http://dx.doi.org/10.1016/j.it.2009.02.002
113. H.Chi. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 2012; 12(5):325-38; PMID:22517423; http://dx.doi.org/10.1038/nri3198
114. T.Osada, G.Chong, R.Tansik, T.Hong, N.Spector, R.Kumar, H.I.Hurwitz, I.Dev, A.B.Nixon, H.K.Lyerly et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57(8):1115-24; PMID:18193223; http://dx.doi.org/10.1007/s00262-007-0441-x
115. I.Melero, A.M.Grimaldi, J.L.Perez-Gracia, P.A.Ascierto. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19(5):997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214
116. J.C.Yang, M.Hughes, U.Kammula, R.Royal, R.M.Sherry, S.L.Topalian, K.B.Suri, C.Levy, T.Allen, S.Mavroukakis et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30(8):825-30; PMID:18049334; http://dx.doi.org/10.1097/CJI.0b013e318156e47e
117. M.G.Ruocco, K.A.Pilones, N.Kawashima, M.Cammer, J.Huang, J.S.Babb, M.Liu, S.C.Formenti, M.L.Dustin, S.Demaria. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clinical Invest 2012; 122(10):3718-30; PMID:22945631; http://dx.doi.org/10.1172/JCI61931
118. S.L.Topalian, C.G.Drake, D.M.Pardoll. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin in Immunol 2012; 24(2):207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009